| Stage | PSA | % of rev | MSA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.4B | 100.00% | $536M | 100.00% | PSA ×2.55 |
| Gross profit | $989M | 72.41% | $244M | 45.53% | PSA +26.9pp |
| Operating income | $317M | 23.20% | $88M | 16.45% | PSA +6.8pp |
| Pre-tax income | $363M | 26.59% | $82M | 15.28% | PSA +11.3pp |
| Net income | $378M | 27.69% | $58M | 10.89% | PSA +16.8pp |
| Stage | PSA | MSA | Gap · A − B |
|---|---|---|---|
| Revenue | $1.4B100.00% | $536M100.00% | PSA ×2.55 |
| Gross profit | 72.41%$989M | 45.53%$244M | PSA +26.9pp |
| Operating income | 23.20%$317M | 16.45%$88M | PSA +6.8pp |
| Pre-tax income | 26.59%$363M | 15.28%$82M | PSA +11.3pp |
| Net income |
None
No disclosed counterparties: PSA.
| 27.69%$378M |
| 10.89%$58M |
| PSA +16.8pp |